NCT05435235

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

Dapagliflozin in the Prevention of Post-Coronary Intervention Acute Kidney Injury

• Status: Suspended
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Albert Einstein Healthcare Network · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To compare the incidence of acute kidney injury (AKI) post percutaneous coronary intervention (PCI) in a Dapagliflozin treated group versus a group managed with the usual standard of care.

Conditions

• Acute Kidney Injury
• Percutaneous Coronary Intervention

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10mg Tab	One tablet daily starting 48h prior to PCI and continuing for 48h post-PCI.

Timeline

• Start date: 2024-09-01
• Primary completion: 2025-06-01
• Completion: 2025-06-01
• First posted: 2022-06-28
• Last updated: 2024-07-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study